27.32USD-3.39%Mkt Cap: 1.27B USDP/E: —Last update: 2026-06-01
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.27B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.91M USD
Revenue/Share—
Last Price27.32 USD
Fiscal Year EndDec 2025
MR Quarter—
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.26
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.15
EPS (TTM)-10.13
EPS (Forward)-2.33
52W Range
23.0032% of range36.61
52W High36.61 USD
52W Low23.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.18%
ROA-32.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-61.48M USD
CapEx (TTM)16.00K USD
FCF Margin—
FCF Yield-3.12%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio18.03
Quick Ratio17.62
Book Value/Sh-186.7180 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)41.75 USD
Target Range36.00 USD – 50.00 USD
# Analysts4
Ownership
Shares Out.46.71M
Float456.13K
Insiders10.78%
Institutions59.90%
Short Interest
Short Ratio1.2d
Short % Out.1.62%
Shares Short758.70K
Technical
SMA 5026.94 (+1.4%)
SMA 20026.94 (+1.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)395.29K
Avg Vol (10d)160.19K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—